Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Antenatal, general
  6. Women Who Refuse Blood Products, Obstetrics (401)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Women Who Refuse Blood Products, Obstetrics (401)

Warning
Please report any inaccuracies or issues with this guideline using our online form

Most women will accept blood transfusion if there is a clinical need and they are fully informed. Some women may refuse transfusion because of specific personal or religious beliefs. The main group of women, who refuse transfusion of allogenic blood or primary blood components (red cells, white cells, plasma and platelets), are practising Jehovah’s Witnesses.

Applicable Unit Policies

 

Antenatal Management

  • At booking Identify women who may decline blood transfusion and transfer to RED pathway. (Highlight in Alerts and Management plan on Badgernet.)
  • Women declining blood transfusion should be booked for hospital delivery in a Consultant led unit. All women should be seen antenatally by  their  Consultant  preferably  before  24+0 weeks,  and advised  about the risk of haemorrhage, including management options and the increased risk of hysterectomy. This must be carefully documented.
  • Complete the refusal of Blood Transfusion Consent Form in file in the base notes. A copy should be given to the woman.(Appendix A) Complete the Advanced Directive. (Appendix B) and again put copy in basenotes and give woman copy.. Ideally by 24+0 weeks.
  • Ensure that the woman’s wishes are documented, ensuring that blood and primary blood components that the woman would not accept, and treatments that she will accept, are clearly documented and consented to. (Appendix A)
  • Arrange anesthetic review antenatally.
  • Blood group and antibody status should be checked routinely and the haemoglobin and serum ferritin should be checked every 6 weeks. Haematinics  should  be  given  throughout  pregnancy  to maximise iron stores. If the ferritin remains low despite oral iron then intravenous iron should be considered.

Elective Delivery

If elective induction is indicated aim to achieve this Monday, Tuesday or Wednesday in order that completed in weekdays. Elective caesarean section must be on a Consultant list. (Appendix D) Cell Salvage should ideally be available.

Intrapartum / Delivery Management

  • Inform Consultant Obstetrician and Anaesthetist when a woman declining blood transfusion is admitted in labour.
  • The labour should be managed routinely, by the most senior medical and midwifery staff available. Student midwives and junior medical staff should not conduct these deliveries.
  • The third stage of labour should be actively managed and routine prophylactic oxytocin should be given.
  • A Consultant Obstetrician should be present at any operative delivery (vaginal or caesarean section) if this is possible.
  • Cell salvage should ideally be available for elective deliveries.

Postnatal Management

  • The woman should not be left alone for at least an hour after delivery – one to one midwifery care.
  • A postnatal MEWS chart should be commenced.
  • After discharge women should be advised to report promptly if they have concerns about bleeding during the puerperium. Haematinics should be continued.

Management of Haemorrhage

  • The principle of management of haemorrhage is to minimise blood loss and avoid delay. Rapid decision-making may be necessary, particularly with regard to surgical intervention.
  • If significant bleeding occurs at any time during pregnancy, labour or the puerperium, the Consultant Obstetrician, Anaesthetist and Haematologist should immediately be informed. A second Obstetric &  Gynaecology Consultant  should  be  contacted  if laparotomy required.  This surgeon must  be suitably  skilled  to aid major surgery.
  • Start the standard management promptly (pdf link to Appendix E). The threshold for intervention should be lower than in other patients. Extra vigilance should be exercised to quantify any abnormal bleeding and to detect complications, such as clotting abnormalities, as promptly as possible.
  • Intravenous crystalloid should be used. Do not use Dextran
  • If available cell salvage may be life-saving if there is substantial blood loss. A cell sa ver set with additional leucocyte depletion filter to remove amniotic fluid components (order code RS1VAE) together with separate suction has been reported as a potential life-saving technique during caesarean section.
  • The woman and her family should be kept fully informed about what is happening  by  an informed  member  of  Massive obstetric  haemorrhage  can rapidly  become life threatening.  If standard treatment is not controlling the bleeding, she should be advised that blood transfusion is strongly recommended.
  • Surgical management of bleeding should include use of a B-Lynch Suture, intrauterine balloon, interventional radiology techniques, internal iliac artery ligation and hysterectomy. The woman’s life may be saved by timely hysterectomy, though even this does not guarantee   If hysterectomy  is  performed  the  uterine arteries  should  be  clamped  as  early  as  possible  in the procedure. Subtotal hysterectomy can be just as effective as total hysterectomy, as well as being quicker and safer. The timing of hysterectomy is a decision for the consultant on site. A second Consultants presence is advised only if this does not cause undue delay in definitive treatment.
  • If the woman requires transferred to an intensive care unit, the management there should include erythropoetin, parenteral iron therapy and adequate protein for haemoglobin Hyperbaric oxygen therapy is an option in life threatening anaemia due to PPH but availability is limited.
  • If, in spite of all care, the woman dies, her relatives require support like any other bereaved family. It is very distressing for staff to have to watch a woman bleed to death while refusing effective treatment. Support should also be promptly available for staff in these circumstances. Early contact with the Perinatal Counselling Service.

Legal and Ethical Aspects

Any patient is entitled to change her mind about a previously agreed treatment plan.

  • The doctor  must be  satisfied  that the woman is  not being subjected to pressure from others (including staff). It is reasonable to ask the accompanying persons to leave the room so that the doctor (with a midwife or other colleague) can ask her whether she is making her decision of her own free will. If she maintains her refusal to accept blood or blood products, her wishes should be respected. The legal position is that any adult patient (i.e. 16 years old or over) who has the necessary mental capacity  to do  so is entitled to refuse treatment, even if it is likely that  refusal will result in the patient’s death. No other person is  legally able to consent to treatment for that adult or to refuse treatment on that person’s behalf.

Note: This document does not apply to the neonate.

 

HELP AND ADVICE

Further help and advice on the non-blood management of Jehovah’s Witnesses may be obtained from the Hospital Liaison Committee of Jehovah’s Witnesses. They operate a 24/7 assistance arrangement. Contacts are as shown below:

Harry Crawford

22 Loch Goil

East Kilbride

Glasgow

G74 2EJ

Tel 01355 220 674

Mobile 07711 367409

harry@harry-crawford.com

John Allum

110 Brownside Road Cambuslang

GLASGOW

G72 8AF

Tel 0141.641.6206

Mobile 07836.704774

johnallum@hlcglasgow.co.uk

John Flack

17 Croft Road Balmore

TORRANCE

G64 4AL

Tel 01360.621865

Mobile 07775.837513

Johnflack080238@aol.com

Editorial Information

Last reviewed: 13/03/2018

Next review date: 31/03/2023

Author(s): Ann Duncan.

Approved By: Obstetrics Clinical Guideline Group

Document Id: 401

References

Useful Publications

  1. Royal College of Surgeons. Code of Practice for the Surgical Management of Jehovah’s Witness . London: IBSA Press; 2002
  2. Association of Anaesthetists of Great Britain and Ireland. Management of Anaesthesia for Jehovah’s Witness. 2nd London:AAGBI;2005 [www.aagbi.org/publications/guidelines/docs/jehovah’.pdf]
  3. RCOG green-top guideline for Blood Transfusion in Obstetrics- 47; July 2008